SMS Lifesciences India Past Earnings Performance
Past criteria checks 5/6
SMS Lifesciences India has been growing earnings at an average annual rate of 0.3%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 2.5% per year. SMS Lifesciences India's return on equity is 10.3%, and it has net margins of 6.9%.
Key information
0.3%
Earnings growth rate
0.3%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 2.5% |
Return on equity | 10.3% |
Net Margin | 6.9% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Earnings Working Against SMS Lifesciences India Limited's (NSE:SMSLIFE) Share Price Following 25% Dive
Nov 14Improved Earnings Required Before SMS Lifesciences India Limited (NSE:SMSLIFE) Stock's 58% Jump Looks Justified
Aug 27Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Aug 01SMS Lifesciences India Limited (NSE:SMSLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Jun 13SMS Lifesciences India (NSE:SMSLIFE) Use Of Debt Could Be Considered Risky
Feb 10There's Reason For Concern Over SMS Lifesciences India Limited's (NSE:SMSLIFE) Massive 30% Price Jump
Jan 05Should Shareholders Reconsider SMS Lifesciences India Limited's (NSE:SMSLIFE) CEO Compensation Package?
Sep 23SMS Lifesciences India (NSE:SMSLIFE) Is Paying Out A Dividend Of ₹1.50
Sep 07SMS Lifesciences India (NSE:SMSLIFE) Has Affirmed Its Dividend Of ₹1.50
Aug 24SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 16SMS Lifesciences India (NSE:SMSLIFE) Will Pay A Dividend Of ₹1.50
Sep 02SMS Lifesciences India (NSE:SMSLIFE) Takes On Some Risk With Its Use Of Debt
Jun 03With EPS Growth And More, SMS Lifesciences India (NSE:SMSLIFE) Is Interesting
May 13SMS Lifesciences India's (NSE:SMSLIFE) Solid Profits Have Weak Fundamentals
Nov 23Is Now The Time To Put SMS Lifesciences India (NSE:SMSLIFE) On Your Watchlist?
Jun 21Is SMS Lifesciences India (NSE:SMSLIFE) Using Too Much Debt?
Feb 22SMS Lifesciences India Limited's (NSE:SMSLIFE) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Jan 04Insider Buying: The SMS Lifesciences India Limited (NSE:SMSLIFE) MD & Executive Director Just Bought 19% More Shares
Nov 27Does SMS Lifesciences India (NSE:SMSLIFE) Have A Healthy Balance Sheet?
Nov 24Revenue & Expenses Breakdown
How SMS Lifesciences India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 3,169 | 219 | 528 | 0 |
30 Jun 24 | 3,239 | 179 | 512 | 0 |
31 Mar 24 | 3,060 | 91 | 497 | 0 |
31 Dec 23 | 2,797 | 49 | 486 | 0 |
30 Sep 23 | 3,121 | 46 | 475 | 0 |
30 Jun 23 | 3,079 | 67 | 448 | 0 |
31 Mar 23 | 3,156 | 115 | 440 | 0 |
31 Dec 22 | 3,475 | 189 | 427 | 0 |
30 Sep 22 | 3,505 | 172 | 421 | 0 |
30 Jun 22 | 3,558 | 247 | 414 | 0 |
31 Mar 22 | 3,501 | 253 | 401 | 0 |
31 Dec 21 | 3,366 | 213 | 381 | 0 |
30 Sep 21 | 3,118 | 216 | 351 | 0 |
30 Jun 21 | 2,871 | 147 | 334 | 0 |
31 Mar 21 | 2,656 | 136 | 308 | 0 |
31 Dec 20 | 2,291 | 106 | 290 | 0 |
30 Sep 20 | 2,091 | 76 | 271 | 0 |
30 Jun 20 | 2,237 | 79 | 265 | 0 |
31 Mar 20 | 2,608 | 102 | 267 | 0 |
31 Dec 19 | 3,220 | 127 | 264 | 0 |
30 Sep 19 | 3,970 | 188 | 272 | 0 |
30 Jun 19 | 4,098 | 195 | 241 | 0 |
31 Mar 19 | 3,779 | 178 | 236 | 0 |
31 Dec 18 | 2,997 | 146 | 204 | 0 |
30 Sep 18 | 2,697 | 119 | 194 | 0 |
30 Jun 18 | 2,315 | 85 | 186 | 0 |
31 Mar 18 | 2,130 | 65 | 179 | 0 |
31 Dec 17 | 2,148 | 72 | 179 | 0 |
30 Jun 17 | 2,034 | 90 | 180 | 0 |
31 Mar 17 | 2,159 | 129 | 171 | 0 |
Quality Earnings: SMSLIFE has high quality earnings.
Growing Profit Margin: SMSLIFE's current net profit margins (6.9%) are higher than last year (1.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SMSLIFE's earnings have grown by 0.3% per year over the past 5 years.
Accelerating Growth: SMSLIFE's earnings growth over the past year (377%) exceeds its 5-year average (0.3% per year).
Earnings vs Industry: SMSLIFE earnings growth over the past year (377%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: SMSLIFE's Return on Equity (10.3%) is considered low.